Presence of Interleukin-2 in Urine of Superficial Bladder Cancer Patients After Intravesical Treatment with Bacillus Calmette-Guérin

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 1990 Jan 1

PMID 2337907

Citations 15

Authors

W H De Jong

E C de Boer

A P van der Meijden

P Vegt

P A Steerenberg

F M Debruyne

E J Ruitenberg

Affiliations

Soon will be listed here.

Abstract

Urine samples were obtained from patients with superficial bladder cancer after immunotherapy with bacillus Calmette-Guérin (BCG). The patients were repeatedly (once a week for 6 consecutive weeks) treated with intravesical administration of approximately 5 X 10(8) culturable particles of BCG. Some patients received more than six BCG instillations. The urine samples were investigated for the presence of interleukin-2 (IL-2) in an in vitro bioassay using a murine cytotoxic T cell line (CTTL-16) that shows IL-2-dependent growth. Preliminary experiments indicated the presence of inhibitory factors in the urine. This inhibitory activity was abolished after 24 h dialysis. In a neutralization assay with both polyvalent and monoclonal anti-(human IL-2) antibody it was demonstrated that there was indeed IL-2 in the urine samples. In 8 of 11 patients the presence of IL-2 in the urine was demonstrated. The IL-2 production was directly related to the BCG administration as samples obtained just before the BCG instillation were always negative. In IL-2-positive samples a maximum level of IL-2 was observed between 2 h and 6 h after the BCG instillation. In urine samples obtained 24 h after the BCG IL-2 was not detected. In most patients the urine became positive after the third or fourth PCG instillation.

Citing Articles

Nonmuscle invasive bladder cancer: a primer on immunotherapy.

Maruf M, Brancato S, Agarwal P Cancer Biol Med. 2016; 13(2):194-205.

PMID: 27458527 PMC: 4944546. DOI: 10.20892/j.issn.2095-3941.2016.0020.

Novel immunotherapeutic approaches to the treatment of urothelial carcinoma.

Muthigi A, George A, Brancato S, Agarwal P Ther Adv Urol. 2016; 8(3):203-14.

PMID: 27247630 PMC: 4872187. DOI: 10.1177/1756287216628784.

Detection of inflammatory biomarkers in saliva and urine: Potential in diagnosis, prevention, and treatment for chronic diseases.

Prasad S, Tyagi A, Aggarwal B Exp Biol Med (Maywood). 2016; 241(8):783-99.

PMID: 27013544 PMC: 4950402. DOI: 10.1177/1535370216638770.

Bladder Cancer Immunotherapy: BCG and Beyond.

Askeland E, Newton M, ODonnell M, Luo Y Adv Urol. 2012; 2012:181987.

PMID: 22778725 PMC: 3388311. DOI: 10.1155/2012/181987.

Toll-like receptor agonists in cancer therapy.

Adams S Immunotherapy. 2010; 1(6):949-64.

PMID: 20563267 PMC: 2886992. DOI: 10.2217/imt.09.70.

References

van der Meijden A, De Jong W, de Boer E, Steerenberg P, Debruyne F, Ruitenberg E . Immunological aspects of intravesical administration of Bacillus Calmette-Guérin (BCG) in the guinea pig. Urol Res. 1989; 17(1):47-55. DOI: 10.1007/BF00261051. View

Klein W, Bras G, Misdorp W, Steerenberg P, De Jong W, Tiesjema R . Equine sarcoid: BCG immunotherapy compared to cryosurgery in a prospective randomised clinical trial. Cancer Immunol Immunother. 1986; 21(2):133-40. PMC: 11038812. DOI: 10.1007/BF00199861. View

Watson J, Mochizuki D, Gillis S . T-cell growth factors: interleukin 2. Immunol Today. 2014; 1(6):113-7. DOI: 10.1016/0167-5699(80)90047-X. View

Pizza G, Severini G, MENNITI D, De Vinci C, Corrado F . Tumour regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. Preliminary report. Int J Cancer. 1984; 34(3):359-67. DOI: 10.1002/ijc.2910340312. View

Reitsma D, Guinan P, Lamm D, Khanna O, Brosma S, DeKernion J . Long-term effect of intravesical bacillus Calmette-Guérin (BCG) Tice strain on flat carcinoma in situ of the bladder. Prog Clin Biol Res. 1989; 310:171-85. View

Ratliff T, Gillen D, Catalona W . Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol. 1987; 137(1):155-8. DOI: 10.1016/s0022-5347(17)43909-7. View

Lamm D, Thor D, Harris S, Reyna J, Stogdill V, RADWIN H . Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol. 1980; 124(1):38-40. DOI: 10.1016/s0022-5347(17)55282-9. View

Ratliff T, Haaff E, Catalona W . Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancer. Clin Immunol Immunopathol. 1986; 40(2):375-9. DOI: 10.1016/0090-1229(86)90043-7. View

Guinan P, Shaw M, Ray V . Histopathology of BCG and thiotepa treated bladders. Urol Res. 1986; 14(4):211-5. DOI: 10.1007/BF00441116. View

10.

Rosenberg S . Immunotherapy of cancer using interleukin 2: current status and future prospects. Immunol Today. 1988; 9(2):58-62. DOI: 10.1016/0167-5699(88)91261-3. View

11.

Morales A, Eidinger D, Bruce A . Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976; 116(2):180-3. DOI: 10.1016/s0022-5347(17)58737-6. View

12.

De Jong W, Teppema J, Wagenaar S, Paques M, Steerenberg P, Ruitenberg E . Histological evaluation of immunologically mediated tumor regression of the line 10 guinea pig hepatocarcinoma. Virchows Arch B Cell Pathol Incl Mol Pathol. 1986; 50(3):249-69. DOI: 10.1007/BF02889905. View

13.

Mule J, Yang J, Afreniere R, Shu S, Rosenberg S . Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2. J Immunol. 1987; 139(1):285-94. View

14.

Shapiro A, Ratliff T, Oakley D, Catalona W . Reduction of bladder tumor growth in mice treated with intravesical Bacillus Calmette-Guérin and its correlation with Bacillus Calmette-Guérin viability and natural killer cell activity. Cancer Res. 1983; 43(4):1611-5. View

15.

De Jong W, Steerenberg P, Kreeftenberg J, Tiesjema R, Kruizinga W, VAN NOORLE JANSEN L . Experimental screening of BCG preparations produced for cancer immunotherapy: safety and immunostimulating and antitumor activity of four consecutively produced batches. Cancer Immunol Immunother. 1984; 17(1):18-27. PMC: 11039122. DOI: 10.1007/BF00205492. View

16.

Ratliff T, Shapiro A, Catalona W . Inhibition of murine bladder tumor growth by bacille Calmette-Guerin: lack of a role of natural killer cells. Clin Immunol Immunopathol. 1986; 41(1):108-15. DOI: 10.1016/0090-1229(86)90055-3. View

17.

van der Meijden A, De Jong W, Steerenberg P, Walvoort H, de Boer E, Debruyne F . Intravesical BCG administration in the guinea pig. A histomorphological study. Virchows Arch B Cell Pathol Incl Mol Pathol. 1988; 55(4):207-15. DOI: 10.1007/BF02896577. View

18.

KELLEY D, Ratliff T, Catalona W, Shapiro A, Lage J, BAUER W . Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results. J Urol. 1985; 134(1):48-53. DOI: 10.1016/s0022-5347(17)46976-x. View

19.

COE J, FELDMAN J . Extracutaneous delayed hypersensitivity, particularly in the guinea-pig bladder. Immunology. 1966; 10(2):127-36. PMC: 1423641. View

20.

Debruyne F, van der Meijden A, Geboers A, Franssen M, VAN LEEUWEN M, Steerenberg P . BCG (RIVM) versus mitomycin intravesical therapy in superficial bladder cancer. First results of randomized prospective trial. Urology. 1988; 31(3 Suppl):20-5. View